Incannex receives A$6M R&D tax refund; expects another A$5.1M in 2026

Incannex Healthcare Inc.

Received A$6,039,162 under Australian Government's R&D Tax Incentive Program for FY25.
Expects additional ~A$5.1M later in 2026, total >A$11.1M non-dilutive capital received this year.
Non-dilutive refund strengthens balance sheet, supports clinical programs (IHL-42X, PSX-001) and share repurchase.
CEO states refund obtained without issuing shares; company remains debt-free.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.